Emyria Faces Uptake Challenge After Victorian Clinic Activation
Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.
- Victorian Empax clinic operational with 3 beds
- Over 30 therapists recruited and trained
- First TGA Authorised Prescriber approved
- Dual reimbursement through Medibank and DVA
- Clinic expansion option planned for Q4 2026
Victorian Empax Clinic Launches on Target
Emyria Limited (ASX:EMD) has officially activated its first Empax clinic in Victoria, achieving its Q2 CY2026 milestone with patient treatments now underway. The clinic is housed within Avive Health’s Mornington Peninsula Private Hospital, featuring a purpose-built three-bed facility and an option to add a fourth bed later this year as demand increases. This marks a significant step in Emyria’s national rollout, complementing existing operations in Western Australia and Queensland.
With the Victorian clinic now operational, Emyria bolsters its footprint across three states, aligning with its strategy to scale reimbursable, evidence-based mental health treatments underpinned by growing clinical evidence. The company has established the necessary clinical governance, medication supply, and regulatory frameworks to enable steady patient throughput.
Workforce Expansion and Prescriber Network Growth
The clinic’s clinical workforce has been rapidly assembled, with more than 30 therapists recruited and trained to date. Notably, Emyria has secured its first TGA-approved Authorised Prescriber (AP) psychiatrist in Victoria, with three additional AP applications progressing. This expanding prescriber network is critical for increasing treatment capacity and supporting clinic utilisation as patient demand builds.
These developments build on prior recruitment efforts and workforce expansion initiatives, including a recent targeted campaign in New South Wales, which saw the national clinical workforce surpass 90 trained therapists across multiple locations. The growing pool of authorised prescribers and therapists positions Emyria to meet rising demand for its psychedelic-assisted psychotherapy services across Australia’s key mental health markets.
Dual Reimbursement Pathways Support Revenue Model
Emyria’s Victorian Empax clinic benefits from dual reimbursement pathways, combining private health insurer Medibank coverage with government funding through the Department of Veterans’ Affairs (DVA). These funding streams are already active in the clinic, facilitating patient access and underpinning a repeatable revenue model. The company anticipates further payers, such as Workers Compensation insurers, will join over time to enhance utilisation rates.
This funding framework complements the company’s expanding clinical evidence base, which supports the efficacy of its psychedelic-assisted treatments. Emyria’s approach aims to offer reimbursable therapies for complex mental health conditions, including treatment-resistant depression and PTSD, leveraging its integrated clinical and data platforms.
Emyria’s recent quarterly results highlighted $1.2 million in revenue driven by insurer-backed clinics and strong clinical outcomes, with the Victorian clinic launch contributing to this growth trajectory. The company also continues to advance its national clinic network and global partnership initiatives, positioning itself amid increasing interest in psychedelic therapies worldwide.
Bottom Line?
Emyria’s Victorian clinic activation lays the groundwork for scaling reimbursable mental health treatments, but patient uptake and prescriber approvals will be key to sustaining growth.
Questions in the middle?
- How quickly will additional Authorised Prescribers be approved and onboarded in Victoria?
- What patient volumes and utilisation rates will the new clinic achieve in its first six months?
- Can further reimbursement partnerships, such as with Workers Compensation insurers, be secured to diversify revenue?
